Danaher Nears $9.9B Masimo Acquisition After 4.5% Q4 Sales Growth
Danaher Corp is nearing a $9.9 billion acquisition of Masimo, representing a premium to Masimo’s $7 billion market capitalization. Danaher reported Q4 2025 sales of $6.84 billion, up 4.5% year-over-year, and projects fiscal 2026 adjusted EPS of $8.35 to $8.50.
1. Acquisition Terms
Danaher is set to acquire Masimo for roughly $9.9 billion, offering a significant premium over Masimo’s approximate $7 billion market capitalization; the deal follows activist investor-led governance reforms including a board reshuffle and the founder stepping down.
2. Danaher Financial Performance
In Q4 2025, Danaher delivered sales of $6.84 billion, marking a 4.5% year-over-year increase and surpassing consensus estimates; the company forecasts fiscal 2026 adjusted earnings per share of $8.35 to $8.50, reflecting confidence in its long-term growth trajectory.
3. Strategic Rationale
The acquisition enhances Danaher’s diagnostics and monitoring portfolio by integrating Masimo’s wearable and hospital monitoring technologies; this transaction aligns with Danaher’s 25-year acquisition-driven growth strategy and is expected to unlock cost synergies and cross-selling opportunities.